Symjepi Launches at Discount Compared to EpiPen Generics
January 16, 2019 – Adamis Pharmaceuticals and Sandoz have announced the launch of Symjepi™ 0.3mg (epinephrine) prefilled syringe, touting an “intuitive, user-friendly design” that fits in the palm of the hand. The launch will occur in two phases, the first in institutional settings, and the second in the retail market.
Symjepi’s 0.3mg dosage strength received FDA approval in June 2017. The product offers an alternative to Mylan’s EpiPen® 0.3mg (epinephrine) auto-injector, as well as a lower list price compared to EpiPen generics – $250 instead of $300.
The 0.3mg dosage strength of Symjepi is intended for patients who weigh at least 30kg (66 pounds). A 0.15mg pediatric dosage strength received FDA approval in September 2018, but launch plans for this dosage strength are not yet available. Both dosage strengths are indicated to provide emergency treatment of allergic reactions, including anaphylaxis.